Rights of Use of Data Sample Clauses

Rights of Use of Data. 3.1 Data User may use the Data solely for the Research that is the subject of this Agreement, as defined in Exhibit A, Research Proposal, and may not use it for any other purpose. To conduct additional or different research, Data User must submit a separate Research Proposal, which must be approved by Yale and made part of this Agreement or any subsequent agreements). 3.2 Data User may only disseminate its findings from the Research through peer- reviewed publication in the biomedical literature or a Scientific Meeting (as defined below), consistent with Section 8 of this Agreement. 3.3 Data User may not copy, retransmit or publicly post the Data, or transfer the Data for the purpose of allowing access to the Data by any third party not listed on the application (except as set forth in Section 5.2 below). 3.4 If Data User uses, or permits others to use the Data for any research not described in Exhibit A, Yale may, upon written notice to Data User, immediately terminate this Agreement in accordance with Section 10 and Data User acknowledges and agrees that Yale may publicly post any violation of this Agreement. Yale, or XXXXXXX, will be free to pursue other legal remedies for non-compliance with this provision.
Sample 1Sample 2Sample 3See All (9)
AutoNDA by SimpleDocs
Rights of Use of Data. 3.1 User may use the Data solely for the Research that is the subject of this Agreement, as defined in Exhibit A, Research Proposal, and may not use it for any other purpose. To conduct additional or different research, User must submit a separate Research Proposal, which must be approved by the University and made part of this Agreement or any subsequent agreements). 3.2 User may only disseminate its findings from the Research through peer-reviewed publication in the biomedical literature or a Scientific Meeting (as defined below), consistent with Section 8 of this Agreement. 3.3 User may not copy the Data, or transfer the Data for the purpose of allowing access to the Data by any third party not listed on the application (except as set forth in Section 5.2 below). 3.4 If User uses, or permits others to use the Data for any research not described in Exhibit A, University may, upon written notice to User, immediately terminate this Agreement in accordance with Section 10 and User acknowledges and agrees that University may publicly post any violation of this Agreement. The University, or Medtronic, will be free to pursue other legal remedies for non- compliance with this provision.
Sample 1Sample 2
Rights of Use of Data. 3.1 Data User may use the Data solely for the Research that is the subject of this Agreement, as defined in Exhibit A, Research Proposal, and may not use it for any other purpose. To conduct additional or different research, Data User must submit a separate Research Proposal, which must be approved by Yale and made part of this Agreement or any subsequent agreements). 3.2 Data User may only first disseminate its findings from the Research through peer- reviewed publication in the biomedical literature or a Scientific Meeting (as defined below), except with prior approval from Yale (as stated in section 8.2). Once published in the biomedical literature or a Scientific Meeting, findings can be disseminated in any additional media venue. 3.3 Data User may not copy, retransmit or publicly post the Data, or transfer the Data for the purpose of allowing access to the Data by any third party not listed on the application (except as set forth in Section 5.2 below). 3.4 If Data User uses, or permits others to use the Data for any research not described in Exhibit A, Yale may, upon written notice to Data User, immediately terminate this Agreement in accordance with Section 10 and Data User acknowledges and agrees that Yale may disclose that the Agreement was terminated. Yale, or XXXXXXX, will be free to pursue other legal remedies for non-compliance with this provision.
Sample 1
Rights of Use of Data. 3.1 Data User may use the Data solely for the Research that is the subject of this Agreement, as defined in Exhibit A, Research Proposal, and may not use it for any other purpose. To conduct additional or different research, Data User must submit a separate Research Proposal, which must be approved by Yale and made part of this Agreement or any subsequent agreements). 3.2 Data User may only disseminate its findings from the Research through peer- reviewed publication in the biomedical literature or a Scientific Meeting (as defined below), consistent with Section 8 of this Agreement. 3.3 Data User may not copy, retransmit or publicly post the Data, or transfer the Data for the purpose of allowing access to the Data by any third party not listed on the application (except as set forth in Section 5.2 below). 3.4 If Data User uses, or permits others to use the Data for any research not described in Exhibit A, Yale may, upon written notice to Data User, immediately terminate this Agreement in accordance with Section 10 and Data User acknowledges and agrees that Yale may publicly post any violation of this Agreement. Yale, or SI- BONE, will be free to pursue other legal remedies for non-compliance with this provision up to and including injunctive relief. The Parties hereto agree and acknowledge that misuse or disclosure of Data in breach of this Agreement could cause irreparable harm to Yale and/or SI-BONE for which legal remedy would be insufficient, and agree that equitable remedies including injunction are appropriate.
Sample 1

Related to Rights of Use of Data

  • Rights of Use of the results and of pre-existing rights by the NA and the Union (a) for its own purposes and in particular to make available to persons working for the NA, Union institutions, agencies and bodies and to Member States’ institutions, as well as to copy and reproduce in whole or in part and in an unlimited number of copies." For the rest of this article, the references to the "Union" must be read as reference to "the NA and/or the Union".

  • Use of Data (a) In connection with the provision of the services and the discharge of its other obligations under this Agreement, State Street (which term for purposes of this Section XXIX includes each of its parent company, branches and affiliates (''Affiliates")) may collect and store information regarding a Trust and share such information with its Affiliates, agents and service providers in order and to the extent reasonably necessary (i) to carry out the provision of services contemplated under this Agreement and other agreements between the Trusts and State Street or any of its Affiliates and (ii) to carry out management of its businesses, including, but not limited to, financial and operational management and reporting, risk management, legal and regulatory compliance and client service management.

  • Use of Data by User Registry Operator will permit user to use the zone file for lawful purposes; provided that (a) user takes all reasonable steps to protect against unauthorized access to and use and disclosure of the data and (b) under no circumstances will Registry Operator be required or permitted to allow user to use the data to, (i) allow, enable, or otherwise support the transmission by email, telephone, or facsimile of mass unsolicited, commercial advertising or solicitations to entities other than user’s own existing customers, or (ii) enable high volume, automated, electronic processes that send queries or data to the systems of Registry Operator or any ICANN-­‐accredited registrar.

  • Consent to Use of Data You grant NCR Voyix a perpetual, non-exclusive, irrevocable, sub-licensable, transferrable license to use the data transmitted through the Platform: (a) to provide the NCR Voyix Product and the Platform as well as related products, software, materials and services under this Agreement or another agreement between you and NCR Voyix; (b) for product and service enhancements, as well as research and development purposes; and (c) after it has been aggregated, for analytics, commercial and benchmarking purposes.

  • Source of Data A description of (1) the process used to identify claims in the Population, and (2) the specific documentation relied upon by the IRO when performing the Quarterly Claims Review (e.g., medical records, physician orders, certificates of medical necessity, requisition forms, local medical review policies (including title and policy number), CMS program memoranda (including title and issuance number), Medicare contractor manual or bulletins (including issue and date), other policies, regulations, or directives).‌‌‌

  • Use of Names The Manager and the Fund agree that the Manager has a proprietary interest in the names “DFA” and “Dimensional,” and that the Fund and/or Portfolio may use such names only as permitted by the Manager, and the Fund further agrees to cease use of such names promptly after receipt of a written request to do so from the Manager.

  • Use of Customer Data Verizon, Verizon Affiliates and their respective agents, may use, process and/or transfer Customer Data (including intra-group transfers and transfers to entities in countries that do not provide statutory protections for personal information) as set forth in the Privacy Policy and as necessary: (a) in connection with provisioning of Services; (b) to incorporate Customer Data into databases controlled by Verizon, Verizon Affiliates or their respective agents for the purpose of providing Services; administration; provisioning; invoicing and reconciliation; verification of Customer identity, solvency and creditworthiness; maintenance, support and product development; fraud detection and prevention; sales, revenue and customer analysis and reporting; market and customer use analysis including in the manner described in the Privacy Policy; and (c) to communicate to Customer regarding Services.

  • Benefits of Agreement; No Third-Party Rights The provisions of this Agreement are intended solely to benefit the Member and, to the fullest extent permitted by applicable law, shall not be construed as conferring any benefit upon any creditor of the Company (and no such creditor shall be a third-party beneficiary of this Agreement), and the Member shall have no duty or obligation to any creditor of the Company to make any contributions or payments to the Company.

  • Publicity/Use of Names Neither Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their respective employee(s) in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except for those disclosures expressly authorized under this Article 4. Following execution of this Agreement, either Party may issue a press release announcing the existence of this Agreement in form and substance agreed to in writing by both Parties, such agreement to not be unreasonably withheld or delayed. Each Party agrees not to issue any other press release or other public statement disclosing other information relating to this Agreement or the transactions contemplated hereby without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed; provided that Arvinas agrees that it shall be deemed reasonable for Pfizer to withhold its consent for the disclosure of any information related to a Target or a specific Compound or the amount of any payment made or to be made under this Agreement; and provided further that any disclosure which is required by Law or the rules of a securities exchange, as reasonably advised by the disclosing Party’s counsel, may be made subject to the following. Each Party agrees to provide to the other Party a copy of any public announcement regarding this Agreement or the subject matter thereof as soon as reasonably practicable under the circumstances prior to its scheduled release. Except under extraordinary circumstances or to the extent any such advance notice or notice period is not consistent with applicable Law, each Party shall provide the other with an advance copy of any such announcement at least [**] prior to its scheduled release. Each Party shall have the right to expeditiously review and recommend changes to any such announcement and, except as otherwise required by Law, the Party whose announcement has been reviewed shall remove any information the reviewing Party reasonably deems to be inappropriate for disclosure. The contents of any announcement or similar publicity which has been reviewed and approved by the reviewing Party can be re-released by either Party without a requirement for re-approval. In addition, except to the extent required by Laws in connection with patent enforcement activities conducted in accordance with Article 7, Pfizer shall not use the name “Yale” or “Yale University,” nor any variation or adaptation thereof, nor any trademark, trade name or other designation owned by Yale University, nor the names of any of its trustees, officers, faculty, students, employees or agents, for any purpose without the prior written consent of Yale University in each instance, such consent to be granted or withheld by Yale University in its sole discretion, except that Pfizer may state that it has sublicensed from Yale University one or more of the patents or applications comprising the Yale Licensed Patents.

  • Limitations on Use of Information The Fund agrees not to use the information received for marketing or any other similar purpose without the prior written consent of the Intermediary.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!